We’ve recently updated our valuation analysis.

IRLAB Therapeutics Valuation

Is IRLAB A undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for IRLAB A?

Other financial metrics that can be useful for relative valuation.

IRLAB A key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue5.8x
Enterprise Value/EBITDA31.8x
PEG Ratio-1x

Price to Earnings Ratio vs Peers

How does IRLAB A's PE Ratio compare to its peers?

IRLAB A PE Ratio vs Peers
The above table shows the PE ratio for IRLAB A vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average35.8x
SECARE Swedencare
52.3x32.5%kr7.0b
CAU Cronos Australia
54.9xn/aAU$329.9m
PRPH ProPhase Labs
6.1x-53.9%US$162.6m
INCR InterCure
30.1x77.2%₪731.2m
IRLAB A IRLAB Therapeutics
40.5x-42.1%kr1.7b

Price-To-Earnings vs Peers: IRLAB A is expensive based on its Price-To-Earnings Ratio (40.5x) compared to the peer average (35.8x).


Price to Earnings Ratio vs Industry

How does IRLAB A's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

Price-To-Earnings vs Industry: IRLAB A is expensive based on its Price-To-Earnings Ratio (40.5x) compared to the European Pharmaceuticals industry average (17.1x)


Price to Earnings Ratio vs Fair Ratio

What is IRLAB A's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IRLAB A PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio40.5x
Fair PE Ratio19.2x

Price-To-Earnings vs Fair Ratio: IRLAB A is expensive based on its Price-To-Earnings Ratio (40.5x) compared to the estimated Fair Price-To-Earnings Ratio (19.2x).


Share Price vs Fair Value

What is the Fair Price of IRLAB A when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate IRLAB A's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate IRLAB A's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies